首页 > 最新文献

Journal of Medical Imaging and Radiation Oncology最新文献

英文 中文
Paraganglioma and phaeochromocytoma in adult Fontan patients. 成人丰坦患者中的副神经节瘤和嗜铬细胞瘤。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-13 DOI: 10.1111/1754-9485.13809
Stephanie Bm Tan, Maria Luz Garagiola, Xiaoyang Liu, Tae Kyoung Kim, Ciara Mo Brien

Introduction: The purpose of this study was to address the gap in knowledge in the incidence, presentation and imaging features of PPGL in Fontan patients. It has been hypothesised in the literature that Fontan circulation patients have an increased incidence of these tumours. This study is the largest cohort of adult Fontan patients in North America. The Fontan procedure is a palliative procedure for single ventricle congenital heart disease where the systemic venous return is directed into the pulmonary circulation. Fontan patients are at increased risk of developing several extracardiac complications including phaeochromocytoma and paraganglioma (PPGL).

Methods: This retrospective single-centre study includes all adult patients who were treated between 1 September 2015 and 1 September 2022 in a tertiary referral centre for adult congenital heart disease. Imaging and electronic medical records were retrospectively searched for the presence of PPGL.

Results: Five hundred and forty-seven Fontan patients were included in the study. Three patients had PPGL with an incidence of 0.5%. Two patients were diagnosed with paraganglioma and one with phaeochromocytoma. All patients were female. Median age of Fontan procedure was 1.8 years (range: 1.75-27 years). Median age of PPGL diagnosis was 19 years (range: 12-39 years). Median time from Fontan operation to diagnosis of PPGL was 12 years (range: 10.3-17.2 years).

Conclusion: Fontan patients are at increased risk of PPGL. Clinically, the diagnosis of PPGL is challenging as symptoms and serum markers can be confounding in this population; however, the imaging features of PPGL remain typical making the role of the radiologist crucial.

导言:本研究的目的是填补有关丰坦患者PPGL发病率、表现和影像学特征的知识空白。有文献假设丰坦循环患者的此类肿瘤发病率较高。这项研究是北美最大的成人丰坦患者队列。丰坦手术是一种治疗单心室先天性心脏病的姑息性手术,它将全身静脉回流导入肺循环。丰坦患者罹患多种心外并发症的风险增加,其中包括辉铬细胞瘤和副神经节瘤(PPGL):这项回顾性单中心研究包括2015年9月1日至2022年9月1日期间在一家成人先天性心脏病三级转诊中心接受治疗的所有成人患者。研究人员对影像学和电子病历进行了回顾性检索,以确定是否存在PPGL:研究共纳入547名Fontan患者。三名患者患有PPGL,发生率为0.5%。两名患者被诊断为副神经节瘤,一名患者被诊断为嗜铬细胞瘤。所有患者均为女性。接受丰坦手术的中位年龄为1.8岁(范围:1.75-27岁)。确诊PPGL的中位年龄为19岁(范围:12-39岁)。从Fontan手术到确诊PPGL的中位时间为12年(范围:10.3-17.2年):结论:Fontan患者罹患PPGL的风险增加。临床上,PPGL的诊断具有挑战性,因为在这一人群中,症状和血清标志物可能会造成混淆;然而,PPGL的影像学特征仍然具有典型性,因此放射科医生的作用至关重要。
{"title":"Paraganglioma and phaeochromocytoma in adult Fontan patients.","authors":"Stephanie Bm Tan, Maria Luz Garagiola, Xiaoyang Liu, Tae Kyoung Kim, Ciara Mo Brien","doi":"10.1111/1754-9485.13809","DOIUrl":"https://doi.org/10.1111/1754-9485.13809","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this study was to address the gap in knowledge in the incidence, presentation and imaging features of PPGL in Fontan patients. It has been hypothesised in the literature that Fontan circulation patients have an increased incidence of these tumours. This study is the largest cohort of adult Fontan patients in North America. The Fontan procedure is a palliative procedure for single ventricle congenital heart disease where the systemic venous return is directed into the pulmonary circulation. Fontan patients are at increased risk of developing several extracardiac complications including phaeochromocytoma and paraganglioma (PPGL).</p><p><strong>Methods: </strong>This retrospective single-centre study includes all adult patients who were treated between 1 September 2015 and 1 September 2022 in a tertiary referral centre for adult congenital heart disease. Imaging and electronic medical records were retrospectively searched for the presence of PPGL.</p><p><strong>Results: </strong>Five hundred and forty-seven Fontan patients were included in the study. Three patients had PPGL with an incidence of 0.5%. Two patients were diagnosed with paraganglioma and one with phaeochromocytoma. All patients were female. Median age of Fontan procedure was 1.8 years (range: 1.75-27 years). Median age of PPGL diagnosis was 19 years (range: 12-39 years). Median time from Fontan operation to diagnosis of PPGL was 12 years (range: 10.3-17.2 years).</p><p><strong>Conclusion: </strong>Fontan patients are at increased risk of PPGL. Clinically, the diagnosis of PPGL is challenging as symptoms and serum markers can be confounding in this population; however, the imaging features of PPGL remain typical making the role of the radiologist crucial.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Publication output of RANZCR radiation oncologists in 2022-23. 2022-23 年 RANZCR 放射肿瘤学家的出版成果。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-11 DOI: 10.1111/1754-9485.13807
Daniel Roos, Lisa Milner, Therese Kang, Emma Quinn, Wee Loon Ong

Introduction: The purpose of this work was to determine the current publication output of Royal Australian and New Zealand College of Radiologists radiation oncologists (ROs) to serve as a baseline contributing to future assessment of the effectiveness of the College's Research Action Plan 2024-26.

Methods: An online survey was sent to all ROs in the College's member database in March-April 2024 requesting a list of publications between 2022 and 2023. A PubMed search was performed to cross-check the self-reported publications. Given the low response rate (8%), an additional PubMed search was performed for the non-responders. The primary outcomes were publication proportions and rates, and the secondary outcomes were demographic correlates (gender, country, seniority).

Results: There were 536 eligible ROs (56% males; 80% practicing in Australia; median 12.4 years post-Fellowship) with 1,012 unique publications identified. The proportions of ROs with at least one publication in any-, first- and last-author positions averaged 45%, 15% and 17% per year, respectively. On multivariable analysis, there were statistically significant differences in publications by seniority (higher proportions of last-authorships but lower proportions of first-authorships, for those ≥5 years post-Fellowship) and by country (lower any-, and last-authorships for New Zealand [NZ] than Australia or Singapore). The mean numbers of any-, first- and last-authorships were 1.6, 0.18 and 0.29 per RO per year, respectively. On multivariable analysis, there were statistically significant differences by gender (males had more any-, and first-authorships), seniority (senior ROs had more last-authorships but less first-authorships) and country (lower numbers of any-, and last-authorships for New Zealand).

Conclusion: This organization-wide study provides comprehensive baseline RO publication data and identifies opportunities for the College to further address correlated disparities.

导言:这项工作的目的是确定澳大利亚和新西兰皇家放射肿瘤学院放射肿瘤学家(ROs)目前的出版物产出,作为未来评估学院《2024-26 年研究行动计划》有效性的基线:2024 年 3 月至 4 月,向学院会员数据库中的所有放射科医师发送了一份在线调查,要求他们提供 2022 年至 2023 年期间发表的论文清单。为核对自报的出版物,还进行了 PubMed 搜索。鉴于回复率较低(8%),我们对未回复者进行了额外的 PubMed 搜索。主要结果是发表论文的比例和比率,次要结果是人口统计学相关因素(性别、国家、资历):共有 536 名符合条件的研究员(56% 为男性;80% 在澳大利亚执业;获得研究员资格后的时间中位数为 12.4 年)发表了 1,012 篇独特的论文。在任何作者、第一作者和最后作者位置上至少发表过一篇论文的研究员比例每年平均分别为45%、15%和17%。在多变量分析中,不同资历(获得研究员资格后≥5 年的人员中,最后作者的比例较高,但第一作者的比例较低)和不同国家(新西兰的任何作者和最后作者的比例低于澳大利亚或新加坡)的人员发表的论文在统计上存在显著差异。每名研究员每年获得的任意、第一和最后署名的平均数量分别为 1.6、0.18 和 0.29。在多变量分析中,性别(男性拥有更多的任意和第一作者)、资历(资深研究员拥有更多的最后作者,但第一作者较少)和国家(新西兰的任意和最后作者数量较少)之间的差异具有统计学意义:这项全组织范围的研究提供了全面的研究干事发表论文的基准数据,并为学院进一步解决相关差异问题提供了机会。
{"title":"Publication output of RANZCR radiation oncologists in 2022-23.","authors":"Daniel Roos, Lisa Milner, Therese Kang, Emma Quinn, Wee Loon Ong","doi":"10.1111/1754-9485.13807","DOIUrl":"https://doi.org/10.1111/1754-9485.13807","url":null,"abstract":"<p><strong>Introduction: </strong>The purpose of this work was to determine the current publication output of Royal Australian and New Zealand College of Radiologists radiation oncologists (ROs) to serve as a baseline contributing to future assessment of the effectiveness of the College's Research Action Plan 2024-26.</p><p><strong>Methods: </strong>An online survey was sent to all ROs in the College's member database in March-April 2024 requesting a list of publications between 2022 and 2023. A PubMed search was performed to cross-check the self-reported publications. Given the low response rate (8%), an additional PubMed search was performed for the non-responders. The primary outcomes were publication proportions and rates, and the secondary outcomes were demographic correlates (gender, country, seniority).</p><p><strong>Results: </strong>There were 536 eligible ROs (56% males; 80% practicing in Australia; median 12.4 years post-Fellowship) with 1,012 unique publications identified. The proportions of ROs with at least one publication in any-, first- and last-author positions averaged 45%, 15% and 17% per year, respectively. On multivariable analysis, there were statistically significant differences in publications by seniority (higher proportions of last-authorships but lower proportions of first-authorships, for those ≥5 years post-Fellowship) and by country (lower any-, and last-authorships for New Zealand [NZ] than Australia or Singapore). The mean numbers of any-, first- and last-authorships were 1.6, 0.18 and 0.29 per RO per year, respectively. On multivariable analysis, there were statistically significant differences by gender (males had more any-, and first-authorships), seniority (senior ROs had more last-authorships but less first-authorships) and country (lower numbers of any-, and last-authorships for New Zealand).</p><p><strong>Conclusion: </strong>This organization-wide study provides comprehensive baseline RO publication data and identifies opportunities for the College to further address correlated disparities.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Radiotherapy for node-positive prostate cancer in the PSMA-PET era: The need for prospective clinical trials. PSMA-PET时代结节阳性前列腺癌的放射治疗:前瞻性临床试验的必要性。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-11 DOI: 10.1111/1754-9485.13806
Wee Loon Ong, Therese Min Jung Kang, Andrew Loblaw
{"title":"Radiotherapy for node-positive prostate cancer in the PSMA-PET era: The need for prospective clinical trials.","authors":"Wee Loon Ong, Therese Min Jung Kang, Andrew Loblaw","doi":"10.1111/1754-9485.13806","DOIUrl":"https://doi.org/10.1111/1754-9485.13806","url":null,"abstract":"","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142621984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing DCE-MRI and DSA: Understanding the embolization of hypervascular spinal metastases. 比较 DCE-MRI 和 DSA:了解高血管脊柱转移瘤的栓塞情况。
IF 2.2 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Pub Date : 2024-11-11 DOI: 10.1111/1754-9485.13808
Muhammad Adnan, Ameer Mustafa Farukh, Syed Muhammad Sinaan Ali, Muhammad Mubashir, Imaan Jauhar, Abdul Raheem

This study aims to examine and compare the effectiveness of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and Digital Subtraction Angiography (DSA) in evaluating hypervascular spinal metastases. A comprehensive literature review was conducted, utilizing top-tier databases such as PubMed, Scopus and Google Scholar, to compile an authoritative and up-to-date overview of the current advancements in the field. We synthesized key studies focusing on the advantages, limitations and efficacy of both imaging techniques. DCE-MRI provides a non-invasive method for evaluating tissue morphology, perfusion and vascularity, offering valuable information for cancer diagnosis and treatment monitoring. In contrast, DSA is an invasive procedure primarily used for embolization and diagnosing cerebrovascular events. Both modalities have distinct features regarding image acquisition, contrast agents, resolution and accessibility. DCE-MRI shows promise for cancer-related applications, offering advantages over conventional MRI by incorporating anatomical and hemodynamic parameters. While DSA remains important for cases requiring critical vascular information, further research is necessary to explore its potential therapeutic benefits in assessing vessel patency. Continued investigations are crucial to uncover additional insights and therapeutic applications for both DCE-MRI and DSA in medical imaging.

本研究旨在研究和比较动态对比增强磁共振成像(DCE-MRI)和数字减影血管造影术(DSA)在评估高血管性脊柱转移瘤方面的效果。我们利用 PubMed、Scopus 和 Google Scholar 等顶级数据库进行了全面的文献综述,对该领域的最新进展进行了权威性概述。我们对重点研究进行了归纳,重点介绍了这两种成像技术的优势、局限性和功效。DCE-MRI 提供了一种评估组织形态、灌注和血管的非侵入性方法,为癌症诊断和治疗监测提供了宝贵的信息。相比之下,DSA 是一种侵入性程序,主要用于栓塞和诊断脑血管事件。这两种模式在图像采集、造影剂、分辨率和可及性方面都有不同的特点。DCE-MRI 结合了解剖学和血流动力学参数,比传统磁共振成像更具优势,因此有望应用于癌症相关领域。虽然 DSA 对需要关键血管信息的病例仍然很重要,但仍有必要进一步研究其在评估血管通畅性方面的潜在治疗优势。持续的研究对发现 DCE-MRI 和 DSA 在医学成像中的更多见解和治疗应用至关重要。
{"title":"Comparing DCE-MRI and DSA: Understanding the embolization of hypervascular spinal metastases.","authors":"Muhammad Adnan, Ameer Mustafa Farukh, Syed Muhammad Sinaan Ali, Muhammad Mubashir, Imaan Jauhar, Abdul Raheem","doi":"10.1111/1754-9485.13808","DOIUrl":"https://doi.org/10.1111/1754-9485.13808","url":null,"abstract":"<p><p>This study aims to examine and compare the effectiveness of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and Digital Subtraction Angiography (DSA) in evaluating hypervascular spinal metastases. A comprehensive literature review was conducted, utilizing top-tier databases such as PubMed, Scopus and Google Scholar, to compile an authoritative and up-to-date overview of the current advancements in the field. We synthesized key studies focusing on the advantages, limitations and efficacy of both imaging techniques. DCE-MRI provides a non-invasive method for evaluating tissue morphology, perfusion and vascularity, offering valuable information for cancer diagnosis and treatment monitoring. In contrast, DSA is an invasive procedure primarily used for embolization and diagnosing cerebrovascular events. Both modalities have distinct features regarding image acquisition, contrast agents, resolution and accessibility. DCE-MRI shows promise for cancer-related applications, offering advantages over conventional MRI by incorporating anatomical and hemodynamic parameters. While DSA remains important for cases requiring critical vascular information, further research is necessary to explore its potential therapeutic benefits in assessing vessel patency. Continued investigations are crucial to uncover additional insights and therapeutic applications for both DCE-MRI and DSA in medical imaging.</p>","PeriodicalId":16218,"journal":{"name":"Journal of Medical Imaging and Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":2.2,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142622026","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Medical Imaging and Radiation Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1